Early diagnosis of acute rheumatic fever and rheumatic heart disease as part of a secondary prevention strategy: Narrative review.
diagnosis
echocardiography
rheumatic fever
rheumatic heart disease
secondary prevention
Journal
Journal of paediatrics and child health
ISSN: 1440-1754
Titre abrégé: J Paediatr Child Health
Pays: Australia
ID NLM: 9005421
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
revised:
05
07
2021
received:
25
01
2021
accepted:
14
07
2021
pubmed:
24
7
2021
medline:
25
2
2023
entrez:
23
7
2021
Statut:
ppublish
Résumé
Acute rheumatic fever (ARF) and its sequela rheumatic heart disease (RHD) remain significant causes of morbidity and mortality. In New Zealand, ARF almost exclusively affects Indigenous Māori and Pacific children. This narrative review aims to present secondary interventions to improve early and accurate diagnosis of ARF and RHD, in order to minimise disease progression in New Zealand. Medline, EMBASE and Scopus databases were searched as well as other electronic publications. Included were 56 publications from 1980 onwards. Diagnosing ARF and RHD as early as possible is central to reducing disease progression. Recent identification of specific ARF biomarkers offer the opportunity to aid initial diagnosis and portable echocardiography has the potential to detect undiagnosed RHD in high-risk areas. However, further research into the benefits and risks to children with subclinical RHD is necessary, as well as an economic evaluation.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1385-1390Subventions
Organisme : Health Research Council of New Zealand
ID : 18/079
Informations de copyright
© 2021 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).
Références
Carapetis JR, Beaton A, Cunningham MW et al. Acute rheumatic fever and rheumatic heart disease. Nat. Rev. Dis. Primers. 2016; 2: 15084.
Thomas S, Bennett J, Jack S et al. Descriptive analysis of group a streptococcus in skin swabs and acute rheumatic fever, Auckland, New Zealand, 2010-2016. Lancet Reg. Health 2021; 8: 100101.
Bennett J, Zhang J, Leung W et al. Rising ethnic inequalities in acute rheumatic fever and rheumatic heart disease, New Zealand, 2000-2018. Emerg. Infect. Dis. 2021; 27: 36-46.
Watkins DA, Johnson CO, Colquhoun SM et al. Global, regional, and national burden of rheumatic heart disease, 1990-2015. N. Engl. J. Med. 2017; 377: 713-22.
Heart Foundation of New Zealand. New Zealand Guidelines for Rheumatic Fever: Diagnosis, Management and Secondary Prevention of Acute Rheumatic Fever and Rheumatic Heart Disease. Auckland, New Zealand: National Heart Foundation of New Zealand; 2014.
Gewitz MH, Baltimore RS, Tani LY et al. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: A scientific statement from the American Heart Association. Circulation 2015; 131: 1806-18.
Jones TD. The diagnosis of rheumatic fever. JAMA 1944; 126: 481-4.
Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect. Dis. 2005; 5: 685-94.
Bland EF, Duckett JT. Rheumatic fever and rheumatic heart disease; a twenty year report on 1000 patients followed since childhood. Circulation 1951; 4: 836-43.
Ash R. Rheumatic infection in childhood; 15 to 20 year follow-up. Am. J. Dis. Child. 1948; 76: 46-52.
Wilson MG, Lubschez R. Longevity in rheumatic fever; based on the experience of 1,042 children observed over a period of 30 years. JAMA 1948; 138: 794-8.
de Dassel JL, de Klerk N, Carapetis JR, Ralph AP. How many doses make a difference? An analysis of secondary prevention of rheumatic fever and rheumatic heart disease. J. Am. Heart Assoc. 2018; 7: e010223.
World Health Organization Technical Report Series. Rheumatic Fever and Rheumatic Heart Disease. Report of a WHO Expert Consultation Geneva, 29 October-1 November 2001. 2004.
Remenyi B, Carapetis J, Wyber R, Taubert K, Mayosi BM. Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease. Nat. Rev. Cardiol. 2013; 10: 284-92.
Wilson N, Mitchelson B, Peat B et al. The New Zealand rheumatic heart disease registry. Heart Lung Circ. 2018; 27 (Suppl. 1): S19-O39.
Oliver J, Robertson O, Zhang J et al. Ethnically disparate disease progression and outcomes among acute rheumatic fever patients in New Zealand, 1989-2015. Emerg. Infect. Dis. 2021; 27: 1893-1902.
Gurney J, Chong A, Culliford-Semmens N, Tilton E, Wilson NJ, Sarfati D. The benefits and harms of rheumatic heart disease screening from the perspective of the screened population. Int. J. Cardiol. 2016; 221: 734-40.
Kotit S, Said K, ElFaramawy A, Mahmoud H, Phillips DIW, Yacoub MH. Prevalence and prognostic value of echocardiographic screening for rheumatic heart disease. Open Heart 2017; 4: e000702.
Zühlke L, Engel ME, Lemmer CE et al. The natural history of latent rheumatic heart disease in a 5 year follow-up study: A prospective observational study. BMC Cardiovasc. Disord. 2016; 16: 46.
Saxena A, Ramakrishnan S, Roy A et al. Prevalence and outcome of subclinical rheumatic heart disease in India: The RHEUMATIC (Rheumatic Heart Echo Utilisation and Monitoring Actuarial Trends in Indian Children) study. Heart 2011; 97: 2018-22.
Beaton A, Okello E, Engelman D et al. Determining the impact of Benzathine penicillin G prophylaxis in children with latent rheumatic heart disease (GOAL trial): Study protocol for a randomized controlled trial. Am. Heart J. 2019; 215: 95-105.
RHD Australia (ARF/RHD Writing Group). The 2020 Australian Guideline for Prevention, Diagnosis and Management of Acute Rheumatic Fever and Rheumatic Heart Disease, 3rd edn. Darwin, Northern Territory, Australia; 2020.
Beaton A, Carapetis J. The 2015 revision of the Jones criteria for the diagnosis of acute rheumatic fever: Implications for practice in low-income and middle-income countries. Heart Asia 2015; 7: 7-11.
Szczygielska I, Hernik E, Kołodziejczyk B, Gazda A, Maślińska M, Gietka P. Rheumatic fever - New diagnostic criteria. Reumatologia 2018; 56: 37-41.
Güler M, Laloğlu F, Olgun H, Ceviz N. Clinical characteristics of pediatric patients with first-attack acute rheumatic fever following the updated guideline. Turk. Pediatri. Ars. 2019; 54: 220-4.
Güler M, Laloğlu F, Ceviz N. Changes in valvular regurgitation in mid-term follow-up of children with first attack acute rheumatic fever: First evaluation after the updated Jones criteria. Cardiol. Young 2020; 30: 369-71.
Alqanatish J, Alfadhel A, Albelali A, Alqahtani D. Acute rheumatic fever diagnosis and management: Review of the global implications of the new revised diagnostic criteria with a focus on Saudi Arabia. J. Saudi Heart Assoc. 2019; 31: 273-81.
Pereira BÁF, Belo AR, Silva NAD. Rheumatic fever: Update on the Jones criteria according to the American Heart Association review - 2015. Rev. Bras. Reumatol. Engl. Ed. 2017; 57: 364-8.
Jack S, Moreland NJ, Meagher J, Fittock M, Galloway Y, Ralph AP. Streptococcal serology in acute rheumatic fever patients: Findings from 2 high-income, high-burden settings. Pediatr. Infect. Dis. J. 2019; 38: e1-6.
Parks T, Smeesters PR, Curtis N, Steer AC. ASO titer or not? When to use streptococcal serology: A guide for clinicians. Eur. J. Clin. Microbiol. Infect. Dis. 2015; 34: 845-9.
Steer AC, Smeesters PR, Curtis N. Streptococcal serology: Secrets for the specialist. Pediatr. Infect. Dis. J. 2015; 34: 1250-2.
Johnson DR, Kurlan R, Leckman J, Kaplan EL. The human immune response to streptococcal extracellular antigens: Clinical, diagnostic, and potential pathogenetic implications. Clin. Infect. Dis. 2010; 50: 481-90.
Hanson-Manful P, Whitcombe AL, Young PG et al. The novel Group A Streptococcus antigen SpnA combined with bead-based immunoassay technology improves streptococcal serology for the diagnosis of acute rheumatic fever. J. Infect. 2018; 76: 361-8.
Whitcombe AL, Hanson-Manful P, Jack S et al. Development and evaluation of a new triplex immunoassay that detects group a streptococcus antibodies for the diagnosis of rheumatic fever. J. Clin. Microbiol. 2020; 58: e00300-20.
Epçaçan S, Yücel E. Serum periostin levels in acute rheumatic fever: Is it useful as a new biomarker? Paediatr. Int. Child Health 2020; 40: 111-6.
Karatas Z, Baysal T, Alp H, Toker A. Serum tenascin-C: A novel biomarker for diagnosis and predicting prognosis of rheumatic carditis? J. Trop. Pediatr. 2013; 59: 476-82.
Karataş Z, Baysal T, Şap F, Alp H, Mehmetoğlu I. Increased ischaemia-modified albumin is associated with inflammation in acute rheumatic fever. Cardiol. Young 2014; 24: 430-6.
Kim ML, Martin WJ, Minigo G et al. Dysregulated IL-1β-GM-CSF axis in acute rheumatic fever that is limited by hydroxychloroquine. Circulation 2018; 138: 2648-61.
Chung AW, Ho TK, Hanson-Manful P et al. Systems immunology reveals a linked IgG3-C4 response in patients with acute rheumatic fever. Immunol. Cell Biol. 2020; 98: 12-21.
WHO programme for the prevention of rheumatic fever/rheumatic heart disease in 16 developing countries: report from Phase I (1986-90). WHO Cardiovascular Diseases Unit and principal investigators. Bull. World Health Organ. 1992; 70: 213-8.
John Willis Hurst VF, Alexander RW. Hurst's the Heart. New York: McGraw-Hill Professional; 2001.
Marijon E, Ou P, Celermajer DS et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N. Engl. J. Med. 2007; 357: 470-6.
Tompkins DG, Boxerbaum B, Liebman J. Long-term prognosis of rheumatic fever patients receiving regular intramuscular benzathine penicillin. Circulation 1972; 45: 543-51.
Tadele H, Mekonnen W, Tefera E. Rheumatic mitral stenosis in children: More accelerated course in sub-Saharan patients. BMC Cardiovasc. Disord. 2013; 13: 95.
Carapetis JR, Hardy M, Fakakovikaetau T et al. Evaluation of a screening protocol using auscultation and portable echocardiography to detect asymptomatic rheumatic heart disease in Tongan schoolchildren. Nat. Clin. Pract. Cardiovasc. Med. 2008; 5: 411-7.
Bhaya M, Panwar S, Beniwal R, Panwar RB. High prevalence of rheumatic heart disease detected by echocardiography in school children. Echocardiography 2010; 27: 448-53.
Reményi B, Wilson N, Steer A et al. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease - An evidence-based guideline. Nat. Rev. Cardiol. 2012; 9: 297-309.
Weinberg J, Beaton A, Aliku T, Lwabi P, Sable C. Prevalence of rheumatic heart disease in African school-aged population: Extrapolation from echocardiography screening using the 2012 World Heart Federation Guidelines. Int. J. Cardiol. 2016; 202: 238-9.
Beaton A, Aliku T, Okello E et al. The utility of handheld echocardiography for early diagnosis of rheumatic heart disease. J. Am. Soc. Echocardiogr. 2014; 27: 42-9.
Beaton A, Lu JC, Aliku T et al. The utility of handheld echocardiography for early rheumatic heart disease diagnosis: A field study. Eur. Heart J. Cardiovasc. Imaging 2015; 16: 475-82.
Roberts K, Maguire G, Brown A et al. Echocardiographic screening for rheumatic heart disease in high and low risk Australian children. Circulation 2014; 129: 1953-61.
Engelman D, Kado JH, Reményi B et al. Teaching focused echocardiography for rheumatic heart disease screening. Ann. Pediatr. Cardiol. 2015; 8: 118-21.
Engelman D, Wheaton GR, Mataika RL et al. Screening-detected rheumatic heart disease can progress to severe disease. Heart Asia 2016; 8: 67-73.
Engelman D, Kado JH, Reményi B et al. Focused cardiac ultrasound screening for rheumatic heart disease by briefly trained health workers: A study of diagnostic accuracy. Lancet Glob. Health 2016; 4: e386-94.
Engelman D, Mataika RL, Ah Kee M et al. Clinical outcomes for young people with screening-detected and clinically-diagnosed rheumatic heart disease in Fiji. Int. J. Cardiol. 2017; 240: 422-7.
Paar JA, Berrios NM, Rose JD et al. Prevalence of rheumatic heart disease in children and young adults in Nicaragua. Am. J. Cardiol. 2010; 105: 1809-14.
Beaton A, Aliku T, Dewyer A et al. Latent rheumatic heart disease: Identifying the children at highest risk of unfavorable outcome. Circulation 2017; 136: 2233-44.
Rémond M, Atkinson D, White A et al. Are minor echocardiographic changes associated with an increased risk of acute rheumatic fever or progression to rheumatic heart disease? Int. J. Cardiol. 2015; 198: 117-22.
Bertaina G, Rouchon B, Huon B et al. Outcomes of borderline rheumatic heart disease: A prospective cohort study. Int. J. Cardiol. 2017; 228: 661-5.
Bhaya M, Beniwal R, Panwar S, Panwar RB. Two years of follow-up validates the echocardiographic criteria for the diagnosis and screening of rheumatic heart disease in asymptomatic populations. Echocardiography 2011; 28: 929-33.
Zimmerman M, Scheel A, DeWyer A et al. Determining the risk of developing rheumatic heart disease following a negative screening echocardiogram. Front. Cardiovasc. Med. 2021; 8: 632621.
Mirabel M, Fauchier T, Bacquelin R et al. Echocardiography screening to detect rheumatic heart disease: A cohort study of schoolchildren in French Pacific Islands. Int. J. Cardiol. 2015; 188: 89-95.
Perelini F, Blair N, Wilson N, Farrell A, Aitken A. Family acceptability of school-based echocardiographic screening for rheumatic heart disease in a high-risk population in New Zealand. J. Paediatr. Child Health 2015; 51: 682-8.
Ploutz M, Aliku T, Bradley-Hewitt T et al. Child and teacher acceptability of school-based echocardiographic screening for rheumatic heart disease in Uganda. Cardiol. Young 2017; 27: 82-9.